Skip to main content
. 2023 Apr 10;8(1):11. doi: 10.1186/s41231-023-00144-w

Table 3.

Cancer Gene Therapy Clinical Trials conducted at HFH using HFH developed vectors

IND IRB Virus Virus Dose Rx Site Patient # Phase Status
11,253 4809 CD/TKrep-ADP 1 × 1012 Arm1: GT + IMRT 80 Gy, Arm2: IMRT 80 Gy Prostate 44 II

Closed

11/23/21
11,253 2800 CD/TKrep-ADP 1 × 1011 1 × 1012 GT + IMRT 74 Gy Prostate 9 I Closed, 10/14/14
16,536 9829 CD/TKrep-IL-12

1 × 1010 3 × 1010 1 × 1011 3 × 1011

1 × 1012

 GT only Prostate 15 I Open*
16,536 11,260 CD/TK-rep-IL-12

1 × 1011 3 × 1011

1 × 1012

 GT + Chemo Pancreas 12 I Completed
12,786 3828 CD/TKrep-hNIS 1 × 1011 1 × 1012 GT + IMRT 76 Gy Prostate 19 I Closed, 3/11/14
8436 361 CD/TKrep

1 × 1010

1 × 1011

1 × 1012

 GT only Prostate 16 I Closed, 6/25/12
9852 588 CD/TKrep 1 × 1012 GT + EBRT 70–74 Gy Prostate 15 I Closed, 3/11/14
11,253 15,295 CD/TKrep-ADP 1 × 1011 3 × 1011 1 × 1012 GT + SRS (8 Gy*3) Glioma 9–18 I Open/recruiting

Open*: Not recruiting new patients, long term follow-up only. IRB not yet officially closed